Delivery Order SPE2DB20D1100-SPE2DB25FE0NK
- Not listed
- The Defense Logistics Agency has awarded a delivery order valued at $120,192.80 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of May 15, 2025. The awardee, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $24,038.58 to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed price delivery order with an ultimate completion date of June 24, 2025, and represents a non-competitive, non-set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $136,567.97 delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials on April 24, 2025, with completion expected by May 15, 2025. This firm fixed-price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $96,154.24 to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 24, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. Ocrevus is a monoclonal antibody therapeutic used to treat multiple sclerosis,...
- The Defense Logistics Agency awarded a $12,019.28 firm fixed price delivery order to AmerisourceBergen Drug Corp for 300 mg/10 mL vials of Ocrevus, a specialty pharmaceutical used to treat multiple sclerosis and other autoimmune conditions. The contract, issued on August 1, 2025, with an ultimate completion date of August 22, 2025, was competitively awarded with no set-aside designation. Performance will take place at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $48,077.16 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials. This non-set-aside, firm fixed price delivery order is scheduled for completion by September 3, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. Ocrevus is a specialty pharmaceutical product used in the treatment of multiple sclerosis, reflecting the critical role AmerisourceBergen plays in supplying...
- The Defense Logistics Agency awarded a delivery order valued at $24,038.58 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on August 18, 2025. The contract is firm fixed price with no set-aside designation and is scheduled for completion by September 9, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,019.28 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials. This firm fixed price contract, awarded on July 23, 2025, with an ultimate completion date of August 13, 2025, represents a competitively awarded, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location....
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $120,192.80 by the Defense Logistics Agency on September 18, 2025, for the supply of Ocrevus 300 mg/10 ml vials. This firm fixed-price delivery order, which carries an ultimate completion date of October 9, 2025, represents a competitively awarded contract with no set-aside designation. The contract will be fulfilled from the vendor's Conshohocken,...
- The Defense Logistics Agency awarded a $24,038.58 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on September 8, 2025, with an ultimate completion date of September 29, 2025. This non-set-aside competitive award represents a single delivery order issued against AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's facility in Conshohocken,...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE0NKDelivery Order
The Defense Logistics Agency awarded a $120,192.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials. This is a non-set-aside competitive award with an ultimate completion date of October 9, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the contract at its corporate office location. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime contract vehicle running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Ocrevus is a specialty biologic medication used to treat multiple sclerosis, positioning this delivery order within AmerisourceBergen's broader portfolio of neurological and specialty pharmaceutical products supplied to federal customers. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen demonstrates substantial capability in fulfilling specialized medication requirements across the Defense Health System. The company's contract performance record reflects consistent ability to meet federal procurement standards through open competition and to manage both high-volume commodity supply and specialized pharmaceutical deliveries across multiple therapeutic domains supporting military personnel and veterans.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $120.2k | 9/18/25 |